Compare Gilead Sciences, Inc. (GILD) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $107.45. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| GILD | LQD | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $112.91 |
52-Week Low | $108.22 | $106.96 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LQD trades at $107.335, up 0.12% on the day, with a bearish technical signal driven by moving averages. The ETF shows oversold RSI readings below 30, indicating potential for a near-term bounce. Recent dividends include $0.42 paid in May 2026, with fixed income ETFs gaining investor attention amid economic uncertainty.
Outlook remains cautious due to bearish technicals and interest rate sensitivity. Opportunities exist for income-focused investors via dividends, but risks include Fed policy shifts and inflation pressures. Bond ETF flows are strong, yet narrowing market breadth caps conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
